Larimar Therapeutics, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 35.36 million compared to USD 50.64 million a year ago. Basic loss per share from continuing operations was USD 1.37 compared to USD 2.95 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.38 USD | +4.24% | -6.46% | +62.20% |
May. 21 | Sector Update: Health Care Stocks Steady Premarket Tuesday | MT |
May. 21 | Investors Tread Cautiously as Nvidia Earnings Loom, Driving Muted Premarket Action for US Equity Futures | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+62.20% | 471M | |
+9.83% | 115B | |
+10.80% | 105B | |
-10.84% | 22.71B | |
-0.61% | 21.83B | |
-10.84% | 18.18B | |
-41.92% | 16.52B | |
-15.11% | 16.01B | |
+6.62% | 14.14B | |
+17.53% | 10.71B |
- Stock Market
- Equities
- LRMR Stock
- News Larimar Therapeutics, Inc.
- Larimar Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022